Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells: An experimental study

Chemotherapy

Volumn 54, Issue 3, 2008, Pages 209-216

  Eskiocak, Uǧur ^a   Işeri, Ozlem Darcansoy ^a   Kars, Meltem Demirel ^a   Biçer, Atilla ^a   Gunduz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Bax; Bcl 2; Bcl xL; Doxorubicin; MCF 7; MDR; Telomerase

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL COUNT; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; TELOMERASE;

EID: 46449084886     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140464     Document Type: Article

References (37)

1. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, Shippen-Lentz D: Recognition and elongation of telomeres by telomerase. Genome 1989;31:553-560.
2. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997;17:498-502.
3. Healy KC: Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Oncol Res 1995;7:121-130.
4. Sangrajrang S, Fellous A: Taxol resistance. Chemotherapy 2000;46:327-34.
5. Kwok TT, Mok CH, Menton-Brennan L: Upregulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 1994;54:2834-2836.
6. Ishikawa T, Kamiyama M, Hisatomi H, Ichikawa Y, Momiyama N, Hamaguchi Y, Hasegawa S, Narita T, Shimada H: Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells. Cancer Lett 1999;141:187-194.
7. Akiyama M, Horiguchi-Yamada J, Saito S, Hoshi Y, Yamada O, Mizoguchi H, Yamada H: Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer 1999;35:309-315.
8. Kiyozuka Y, Yamamoto D, Yang J, Uemura Y, Senzaki H, Adachi S, Tsubura A: Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 2000;20:203-212.
9. Cressey TR, Tilby MJ, Newell DR: Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Eur J Cancer 2002;38:586-593.
10. Zhang RG, Guo LX, Wang XW, Xie H: Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin. World J Gastroenterol 2002;8:827-831.
11. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B: The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003;140:133-143.
12. Nuessler V, Stotzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmanns W: Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 1999;13:1864-1872.
13. O'Driscoll L, Clynes M: Molecular markers of multiple drug resistance in breast cancer. Chemotherapy 2006;52:125-129.
14. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-4511.
15. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-490.
16. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA, Fang B: Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 2001;7:1474-1480.
17. Mandal M, Kumar R: Bcl-2 modulates telomerase activity. J Biol Chem 1997;272:14183-14187.
18. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
19. Gelmini S, Caldini A, Becherini L, Capaccioli S, Pazzagli M, Orlando C: Rapid, quantitative nonisotopic assay for telomerase activity in human tumors. Clin Chem 1998;44:2133-2138.
20. Hou M, Xu D, Björkholm M, Gruber A: Real-time quantitative telomeric repeat amplification protocol for the detection of telomerase activity. Clin Chem 2001;47:519-524.
21. Nemos C, Remy-Martin JP, Adami P, Arbez-Gindre F, Schaal JP, Jouvenot M, Delage-Mourroux R: Improved TRAP-silver staining versus conventional radioactive TRAP assays: quantification of telomerase activity during immortalization and in pathological human endometrium. Clin Biochem 2003;36:621-628.
22. Dalla Torre CA, Maciel RM, Pinheiro NA, Andrade JA, De Toledo SR, Villa LL, Cerutti JM: TRAP-silver staining, a highly sensitive assay for measuring telomerase activity in tumor tissue and cell lines. Braz J Med Biol Res 2002;35:65-68.
23. Wen JM, Sun LB, Zhang M, Zheng MH: A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Pathol 1998;51:110-112.
24. Bacus SS, Kiguchi K, Chin D, King CR, Huberman E: Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/ neu antigen. Mol Carcinogen 1990;3:350-362.
25. Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J: Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006;26:4559-4568.
26. Kars MD, Işeri OD, Ural AU, Gündüz U: In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 2007;27:4031-4037.
27. Chomczynski PS: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162: 156-159.
28. Ogretmen B, Safa AR: Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-κB/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 1999;38:2189-2199.
29. Xiong J, Fan S, Meng Q, Schramm L, Wang C, Bouzahza B, Zhou J, Zafonte B, Goldberg ID, Haddad BR, Pestell RG, Rosen EM: BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol 2003;23:8668-8690.
30. Assaf H, Azouri H, Pallardy M: Ochratoxin A induces apoptosis in human lymphocytes through down-regulation of Bcl-xL. Toxicol Sci 2004;79:335-344.
31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
32. Bassam BJ, Caetano-Anolles G, Gresshoff PM: Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 1991;196:80-83.
33. Abramoff MD, Magelhaes PJ, Ram SJ: Image processing with image. J Biophoton Int 2004;11:36-42.
34. Lanvers-Kaminsky C, Winter B, Koling S, Frodermann B, Braun Y, Schaefer KL, Diallo R, Koenemann S, Wai D, Willich N, Poremba C, Schuck A: Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncol Rep 2005;14:751-758.
35. Zhu X, Kumar R, Mandal M, Sharma N, Sharma HW, Dhingra U, Sokoloski JA, Hsiao R, Narayanan R: Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 1996;93:6091-6095.
36. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M: Cloning of human telomerase catalytic subunit gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-557.
37. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M: Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 2003;163:859-867.